Liangjiang to work with top multinational medical company

The signing ceremony for the Danaher Western China Innovation Center takes place in Liangjiang New Area, Southwest China's Chongqing municipality, on March 31. [Photo/liangjiang.gov.cn]

On March 31, Liangjiang New Area and Danaher – a leading global life sciences and diagnostics innovator – signed a strategic cooperation agreement to jointly establish the Danaher Western China Innovation Center.

The center is set to accelerate the medical research and innovation transformation in the Chengdu-Chongqing region. This also marked the first introduction of a Fortune 500 multinational pharmaceutical enterprise project in the new area.

Danaher is expected to build a high-level innovation platform in the new area, as well as to construct a system for research and development, experimentation, training, and project incubation. The company will also realize the seamless integration of production, education, research, and applications.

Peng Yang, global vice president of Danaher, expressed the company's vision of joining hands with industrial partners to integrate the best policy support, a strong research team, effective clinical research, efficient industrial transformation, timely capital support, and a sustainable business model. This will create a high-level integrated innovation platform for precision medicine and biopharmaceuticals.

As part of this project, Danaher will also establish a life sciences research institute. Once completed, this will be Danaher's third research institute in China, after those set up in Shanghai and Guangzhou.

Currently, Liangjiang has attracted 272 life and health enterprises and has established an industrial cluster that integrates new drug research and development, high-end pharmaceutical production, medical devices, high-value consumables, and biotechnology.